[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"osa\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:osa":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,47,73,104,135,161,185,206,233,255],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100648209","clinical-trial-of-the-cryosa-system-for-the-treatment-of-obstructive-sleep-apnea-oasis-100648209",false,"NCT07720219","Clinical Trial of the Cryosa System for the Treatment of Obstructive Sleep Apnea (OASIS)","Obstructive Sleep Apnea Severity Reduction by AdIpose CryolysiS","(OASIS)","Inclusion Criteria:\n\n1. Participant age is 22 years and older\n2. Participant has failed, is unable to use, unwilling to use or dissatisfied with Positive Airway Pressure (PAP) or mandibular advancement devices (MAD)\n3. Participant is diagnosed with Obstructive Sleep Apnea with an AHI ≥30 OR AHI ≥ 15 and BMI of ≥ 30 at enrollment (CA\u002FMA ≤ 25%)\n4. Participant is willing and capable of receiving the study procedure, completing all the questionnaires and returning for all follow-up evaluations and sleep studies\n5. Participant is willing and capable of providing informed consent\n\nExclusion Criteria:\n\n1. Participant is currently participating in other premarket investigational studies unless approved by Sponsor in writing\n2. Any reason for which, in the judgment of the investigator, the participant is considered to be a poor study candidate, which may include, but is not limited to: any uncontrolled neurological, medical, social, or psychological problems that could complicate the required procedures and evaluations of the study (e.g. uncontrolled Type 1 or 2 diabetes with neuropathy, debilitating acute or chronic cardiac, lung, liver, kidney, central nervous system or psychiatric disease)\n3. Participant has a BMI \\> 40 kg\u002Fm2 at enrollment\n4. Women who are pregnant or of childbearing potential (WOCBP defined as fertile following menarche and until becoming post-menopausal unless permanently sterile) who are unwilling to practice an appropriate method of contraception from screening through 6-month follow-up.\n\n   Concomitant Medication Exclusions\n5. Participant is actively taking ACEs\u002FARBs for hypertension AND is either of black race, of female gender, or \\>65 years of age\n6. Participant is actively undergoing immunotherapy (Allergy shots), and unwilling to wash out of allergy shots at least 2 weeks prior to study procedure\n7. Participant is taking any of the following medications that, in the opinion of the investigator, could affect study endpoints: AD109, benzodiazepines, Z-drugs (zolpidem and eszopiclone), opiates, antipsychotics (neuroleptics), phenothiazines, and prescription stimulants (including Sunosi, Provigil, and Nuvigil)\n\n   Significant Airway Risk Factors\n8. Participants with severe uncontrolled asthma\n9. Participants with a history of angioedema\n10. Participants with hereditary angioedema (confirmed with a Complement Component C4 blood test \\\u003C13mg\u002FdL)\n11. Participant has uncontrolled autoimmune disorders including active thyroid disease, lupus, multiple myeloma, and chronic lymphocytic leukemia that could lead to acquired angioedema\n12. Participant has a history or presence of cold urticaria at the time of screening\n13. Participant has a history of cryoglobulinemia or Paradoxical Adipose Hyperplasia (PAH)\n14. Participant has a history of allergy to glycerin History of Oral\u002FAirway Comorbidities\u002FInterventions\n15. Participant has a prior airway interventions that alter or excise the tissue of the soft palate or the tongue base\n16. Participant has any airway intervention within 12 weeks of scheduled procedure performed to alter or excise the soft tissue of the airway or larynx\n17. Participant has an active, implanted, nerve stimulator for the treatment of OSA\n18. Participant has oral cancer or non-healing oral wounds\n19. Participant has a history of radiation therapy to neck or upper respiratory tract\n20. Participant has other severe sleep disorders that, in the opinion of the investigator, confound functional assessments of sleepiness such as narcolepsy with cataplexy, severe insomnia\u002Finsomnia secondary to chronic pain, PTSD\n\n    Major Anatomical Exclusions\n21. Participant has severe maxillary mandibular insufficiency or obvious severe fixed upper airway obstructions (tumors, polyps, nasal obstruction) that, in the opinion of the investigator, is thought to be the primary cause of OSA\n22. Participant has obstructions identified at the tonsils (palatine tonsils size 3+ or 4+)\n23. Participant has lingual tonsils size 4+\n24. Participant has Friedman tongue position IV\n25. Participant has a mandibular intermolar width \\\u003C 32mm\n26. Participant has trismus as defined by a maximal inter-incisal opening of \\\u003C 35mm\n\n    Significant Comorbidities that Contraindicate Surgery or General Anesthesia\n27. Participant has resistant hypertension, defined as a blood pressure that remains above goal despite concurrent use of three antihypertensive agents of different classes taken at maximally tolerated doses\n28. Diagnosis of any moderate to severe congestive obstructive pulmonary disease (COPD)\n29. Active, severe pulmonary vascular disease (for example pulmonary arterial hypertension or pulmonary embolism).\n30. Uncontrolled Diabetes (including Diabetes Mellitus \\[DM\\] or Insulin Dependent Diabetes Mellitus \\[IDDM\\]) with HbA1c \\>9 at time of screening.\n31. Currently receiving treatment for severe cardiac valvular dysfunction, NYHA Class III or IV heart failure, unstable angina or recent (\\\u003C 12 months) myocardial infarction or severe cardiac arrhythmias\n32. Participants with bleeding event, known bleeding diathesis, impaired immunity for any reason, or heart attack or stroke within the last 12 months\n33. Clinical evidence of severe renal failure (Stage 4 or 5) undergoing dialysis or expected to institute dialysis within 6 months\n34. Participant has contraindication to general anesthesia or, in the opinion of the Investigator, would not be able to tolerate the procedure, including intubation during the procedure\n\n    Lifestyle considerations\n35. Participant is a current smoker or nicotine vaper (\\>1 pack\u002Fday or equivalent)\n36. Participant conducts work or regular activities requiring vigilance (e.g., commercial driver, heavy machine operator, shift worker, etc.) that does not accommodate untreated OSA.\n37. Participant has sleep hygiene behavior that is likely to interfere with measurement outcomes during PSG\n38. Participant exhibits ongoing misuse of alcohol or recreational drugs that would impact either the results of or the participation in a sleep study","ALL","22 Years",{"count":20,"type":21},130,"ESTIMATED","INTERVENTIONAL",[24],"NA","The objective of this study is to evaluate the safety and effectiveness of the Cryosa System when used as intended to perform the Cryosa Procedure.",[27,28,29],"Obstructive Sleep Apnea (OSA)","Sleep Apnea - Obstructive","OSA",[31,32,29,33,34],"OASIS","Crysoa","Cryotherapy","Obstructive Sleep Apnea","NOT_YET_RECRUITING","2026-07-16",{"date":38,"type":39},"2026-07-22","ACTUAL",{"date":41,"type":21},"2026-10",{"date":43,"type":21},"2029-11",{"name":45,"class":46},"Cryosa, Inc.","INDUSTRY",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100458808","the-effect-of-interval-exercise-on-functional-outcomes-in-veterans-with-copd-and-osa-100458808","NCT05254431","The Effect of Interval Exercise on Functional Outcomes in Veterans With COPD and OSA","Inclusion Criteria:\n\n* Diagnosis of COPD and OSA, i.e., Overlap Syndrome Diagnosis of Overlap Syndrome (both COPD and OSA), confirmed in CPRS from spirometry or pulmonary function test of FEV1\u002FFVC \\\u003C70 for COPD and a polysomnogram or home-based study for OSA.\n* Montreal Cognitive Assessment (MoCA) \\>20\n\nExclusion Criteria:\n\n* CAD, as defined by anyone of the following: history of CABG, prior positive stress test for ischemia, infarction or angina or medical problem\n* Orthopedic problems as defined by joint pain limiting ambulation\n* Fall risk, defined as more than 2 falls in the prior month\n* Hospitalization in prior month\n* Daytime home oxygen 6. Participation in structured exercise, defined by the Physical Activity Scale for the Elderly (PASE) as more than 1 hour of activity spent in moderate activity and any strenuous activity performed over prior 7 days.",{"count":54,"type":21},28,[24],"The term \"Overlap Syndrome\" (OS) is used to describe the presence of both chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA) in a single patient. Due to premature aging, patients with OS are prone to developing functional decline up to 20 years earlier than the general population. The International Classification of Functioning, Disability and Health (ICF) evaluates functional status in chronic pulmonary disease globally in 5 domains. The investigators propose to study validated outcomes in 3 of these domains: 1) participation in life situations; 2) physical activity; and 3) cardiovascular health. The investigators long-term goal is to develop an exercise strategy tailored to Veterans with OS which will reduce the risk of functional decline through increased PA.",[58,29],"COPD",[58,29,60],"Overlap Syndrome","RECRUITING","2026-04-21",{"date":64,"type":39},"2026-04-24",{"date":66,"type":39},"2022-04-01",{"date":68,"type":21},"2027-04-01",{"name":70,"class":71},"VA Office of Research and Development","FED",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":84,"conditions":85,"keywords":86,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":72},"100586096","impact-of-muscle-training-device-on-non-severe-osa-100586096","NCT06910930","Impact of Muscle Training Device on Non-Severe OSA","Impact of Muscle Training Device on Non-Severe OSA: A Randomized Controlled Study","Inclusion Criteria:\n\n* Patients diagnosed with mild to moderate obstructive sleep apnea.\n* Age 18 years or older.\n* Patients voluntarily consent to provide information for research purposes.\n\nExclusion Criteria:\n\n* Patients with an average apnea-hypopnea index (AHI) of \\\u003C4 or \\>29 events per hour after repeated diagnosis using a home sleep apnea test.\n* Patients who refused to cease using CPAP during the study process\n* Patients with a history of chronic lung disease.\n* Elderly patients with neurological conditions that impair cognitive function, such as dementia, stroke, or psychiatric disorders.\n* Patients taking medications that may affect muscle function within 3 months before the start of the study.\n* Patients with hypothyroidism or other conditions that may affect muscle function.\n* Patients who consume alcohol at a moderate level or higher","18 Years",{"count":82,"type":21},76,[24],"The goal of this clinical trial is to test for the efficacy of the newly invented device #DidgeriTU with non-severe obstructive sleep apnea. The main question it aims to answer is:\n\n• Can DidgeriTU reduce apnea events in patients with non-severe obstructive sleep apnea? Researchers will compare DidgeriTU with a sham device to see how the apnea event has changed.\n\nParticipants will:\n\n* Use DidgeriTU or sham device for 3 month\n* Do an online questionnaire once a month during the study\n* Home sleep test, lung function test, and tongue strength test at the start and end of the study",[29,34],[87,88,89,90,91,92,93],"Device","EMST","Powerbreathe","didgeridoo","didgeriTU","Expiratory muscle exercise","reverse CPAP","2026-01-17",{"date":96,"type":39},"2026-01-21",{"date":98,"type":39},"2025-05-01",{"date":100,"type":21},"2026-03-15",{"name":102,"class":103},"Thammasat University Hospital","OTHER",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":110,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":114,"conditions":115,"keywords":121,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":72},"100597560","the-use-of-entropy-to-assess-sleep-disordered-breathing-in-chronic-respiratory-disease-100597560","NCT07060079","The Use of Entropy to Assess Sleep Disordered Breathing in Chronic Respiratory Disease","Inclusion Criteria:\n\n* All adult patients (≥ 18years) with chronic respiratory disease with\u002Fwithout SDB.\n* patients who have had previously negative studies as a control group.\n* Subject is able to read, understand, and sign the informed consent form.\n* Willing to sleep with portable monitoring devices.\n\nExclusion Criteria:\n\n* Patients who are under 18 years of age at the time of the index study.\n* Contraindications to the use of portable monitoring.\n* Inability to give informed consent to take part in the study.",true,{"count":112,"type":21},120,"OBSERVATIONAL","Research is being conducted into chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD), asthma, interstitial lung disease, and bronchiectasis. The investigation specifically focuses on sleep-disordered breathing (SDB) in individuals with chronic respiratory disease. SDB encompasses a range of conditions, the most common of which is obstructive sleep apnoea. In obstructive sleep apnoea, periodic pauses in breathing (apnoea) lead to reduced blood oxygen levels. To detect these events, patients typically undergo sleep studies that involve monitoring oxygen saturation, heart rate, and respiratory patterns during sleep. When chronic respiratory disease and SDB coexist, breathing disturbances during sleep may be exacerbated.\n\nTo identify SDB, sleep studies are commonly used to assess oxygen levels, heart rate, and breathing patterns. The objective of this research is to identify differences between patients with chronic respiratory diseases who have SDB and those who do not. This will be achieved by analysing sleep study data using a novel analytical approach. The aim is to determine whether this method can yield more detailed insights into the underlying pathophysiology of these conditions.",[116,117,118,58,119,29,120],"Bronchial Asthma","Bronchiectasis","ILD","OSAHS","Obesity Hypoventilation Syndrome (OHS)",[122,118,123,124,58,125],"SDB","Entropy","bronchiectasis","asthma","2025-07-08",{"date":128,"type":39},"2025-07-11",{"date":130,"type":39},"2025-04-30",{"date":132,"type":21},"2026-09-30",{"name":134,"class":103},"University College, London",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":110,"sex":17,"minAge":80,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":145,"conditions":146,"keywords":149,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":72},"100588698","diagnosing-obstructive-sleep-apnea-using-electromyography-of-the-muscles-of-the-mouth-100588698","NCT06944782","Diagnosing Obstructive Sleep Apnea Using Electromyography of the Muscles of the Mouth","BREATH: Breakthrough Research in Electromyography for the Assessment of Sleep-disordered BreaTHing","Inclusion Criteria:\n\n1. Age 18 years or older\n2. Subject must have completed a prior sleep test.\n\n   1. Subjects may be recruited if the last prior sleep test either determined that they do not have sleep apnea OR they have moderate to severe sleep apnea. No sleep apnea is defined by AHI \\\u003C 5; moderate to severe sleep apnea is defined by AHI \\>= 15.\n   2. To be fully eligible, the prior test result needs to be verified via 2-night home sleep test (using the average AHI from the 2 nights). If OSA status (i.e., AHI\\\u003C5\u002Fh or \\>=15\u002Fh) from the 2-night HST vs last prior sleep test is discordant, then participants will be excluded as screen failures.\n\nExclusion Criteria:\n\n1. Current use of OSA therapy, including PAP (positive airway pressure) or non-invasive ventilation on a daily basis\n2. Prior uvulopalatopharyngoplasty surgery for sleep apnea.\n3. Inability to install WatchPAT ONE application on smartphone or tablet or unwillingness\u002Finability to use the WatchPAT ONE home sleep study device\n4. Prisoners are excluded due to ethical, legal, and practical concerns\n5. Individuals who are pregnant are excluded due to temporary changes in habitus, fluid shifts, and potential changes to oropharyngeal musculature may impact tmEMG assessment. This important subpopulation will be investigated in a later phase study.\n6. Inability to stop tobacco, marijuana, or vaping on the day of testing.\n7. Binge alcohol use behaviors (4+ drinks on the same occasion on 5+ days in the past month).\n8. Medication use that may cause central apnea that in the judgment of the investigators could impact the safety or results of the study\n9. Allergy to benzocaine topical anesthetic or other ester class local anesthetics (lidocaine, etc.)\n10. Current psychiatric illness other than treated mood disorders\n11. Unable or unwilling to provide informed consent or comply with research procedures\n12. Active Cancer due to potential interference with study results\n13. Major comorbidities which in the judgment of the investigators could impact the safety or results of the study\n14. Inability to sign consent and participate in the study in English. This study involves use of an investigational device; the technical nature of the study and the consenting process and consent form make it impractical to include subjects who cannot participate in English.","80 Years",{"count":144,"type":21},60,"The investigators will establish how well a novel, quick, and painless way of measuring muscle activity from the mouth and throat works for detecting sleep apnea. This technology is called transmembraneous electromyography (tmEMG). Leveraging two technologies, a new probe capable of recording muscle activity by lightly touching the muscle, as well as a machine learning model for signal interpretation, the investigators will conduct an initial observational feasibility study in phase 1, followed by a larger observational cohort study in phase 2 to assess the performance of deep learning enhanced tmEMG. The study will address a critical unmet need in sleep apnea diagnostics: the availability of an inexpensive, accurate diagnostic test for screening at point of care.",[27,29,147,148],"Healthy Volunteers","Electromyography",[150,151],"sleep study","polysomnography","2025-04-21",{"date":154,"type":39},"2025-04-25",{"date":156,"type":39},"2025-03-24",{"date":158,"type":21},"2025-09",{"name":160,"class":103},"University of California, San Diego",{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":17,"minAge":167,"maxAge":168,"enrollmentInfo":169,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":171,"conditions":172,"keywords":173,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":72},"100524609","detecting-heart-rate-respiration-and-sleep-with-the-sleeptracker-ai-under-mattress-monitor-100524609","NCT06110962","Detecting Heart Rate, Respiration, and Sleep With the Sleeptracker-AI Under-mattress Monitor","Inclusion Criteria:\n\n* Adults aged 20-90 years old at time of assessment.\n* Attending the Woolcock Institute for an overnight sleep study for investigation of sleep apnoea.\n* Able to give informed consent.\n* Fluent in English.\n\nExclusion Criteria:\n\n* Unable to understand study procedure.\n* Unable to sign informed consent form.","20 Years","90 Years",{"count":170,"type":21},100,"The objective of this study is to simultaneously acquire sleep and breathing data using the under-mattress Sleeptracker (The Sleeptracker-AI Monitor (Fullpower Technologies, California, USA) during routine PSGs in patients who attend the Woolcock Institute for undergoing investigation for possible obstructive sleep apnoea (OSA).",[29],[174,175,151],"validation study","Sleeptracker-AI","2025-03-25",{"date":178,"type":39},"2025-03-28",{"date":180,"type":39},"2024-07-10",{"date":182,"type":21},"2028-10-10",{"name":184,"class":103},"Woolcock Institute of Medical Research",{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":17,"minAge":191,"maxAge":142,"enrollmentInfo":192,"targetDuration":4,"studyType":22,"phases":194,"briefSummary":195,"conditions":196,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":72},"100523090","reversible-effect-of-falling-ventilatory-drive-in-drive-dependent-osa-100523090","NCT06091098","Reversible Effect of Falling Ventilatory Drive in Drive-dependent OSA","Inclusion Criteria:\n\n* Diagnosed OSA (AHI≥15 events\u002Fh reported in a PSG performed within 1 year) or Suspected OSA (snoring, sleepiness, witnessed apneas, other clinical symptoms)\n* Use of CPAP or other therapies is acceptable; individuals will be asked to withhold treatment for 3 days before each study visit. Individuals who are occupational drivers or operate heavy machinery will not be asked to withhold treatment.\n\nExclusion Criteria:\n\n* Any unstable medical conditions\n* Conditions that could meaningfully raise the cardiovascular risks of brief low-dose hypercapnic-hypoxic inspired gas mixture: heart failure (LVEF\\\u003C45% if known), recent cardiovascular event (\\\u003C12 mo), recent cerebrovascular event (\\\u003C12 mo)\\*\n* Medications known to depress ventilatory drive (e.g. opioids, barbiturates)\n* Conditions likely to increase arousability from sleep: insomnia\n* Other sleep disorders that may complicate establishment of sleep: periodic limb movements (periodic limb movement arousal index \\> 10\u002Fhr), narcolepsy, or parasomnias\n* For intramuscular electrodes and catheter: allergy to lidocaine\n* Highly-sensitive gag reflex. Patients with a self-reported 'highly-sensitive gag reflex', including an affirmative response to 'Do you sometimes gag when brushing your teeth?', will not take part in the physiology studies given the placement of an esophageal catheter\n* For intramuscular electrodes: use of aspirin or other oral anti-platelets \u002F anti-coagulants\n* For oronasal mask: severe claustrophobia\n* Pregnancy or nursing\n\n  * We do not intend to exclude patients with controlled cardiovascular disease (hypertension of any severity, arrhythmias, stents) common in the OSA patient population. The transient gas mixture interventions are mild, short-lived, and act to slow the spontaneous recovery of blood gas levels to prevent cyclic upper airway obstruction as opposed to exacerbating them. Control of breathing studies commonly increase inspired CO2\u002Freduce inspired oxygen (using higher concentrations via rebreathing tests for longer durations) in patients with a range of comorbidities including heart failure. The level of hypercapnic-hypoxia used is equivalent to taking slightly smaller breaths (by about a third, for the standard dose gas mixture 2%CO2\u002F18.5%O2) for several breaths, or skipping a breath (for the highest dose gas mixture 6%CO2\u002F14%O2), physiological changes that typically cause no noticeable oxygen desaturation, and are minimal compared with the effects of the larger ventilation reduction that accompanies OSA.","21 Years",{"count":193,"type":21},36,[24],"Obstructive sleep apnea (OSA) is a highly prevalent disorder that has major consequences for cardiovascular health, neurocognitive function, risk of traffic accidents, daytime sleepiness, and quality of life. For years, a \"classic\" model of OSA has been used to describe the disorder, which fails to capture it's complexity. Recently, a model for OSA called drive-dependent OSA was discovered be more prevalent in the OSA population. The drive-dependent subgroup benefits exclusively from increased ventilation, increased dilator muscle activity, and reduced event risk when drive spontaneously rises. This study seeks to provide direct evidence that reducing the loss of drive prevents the loss of ventilation, pharyngeal muscle activity, and thus the onset of OSA respiratory events, specifically in \"drive-dependent\" but not \"classic\" OSA. This will be achieved using CO2 delivered at precise times during breaths in sleep to prevent loss of overall ventilatory drive.",[29],"2025-03-17",{"date":199,"type":39},"2025-03-19",{"date":201,"type":39},"2024-03-27",{"date":203,"type":21},"2027-12-31",{"name":205,"class":103},"Brigham and Women's Hospital",{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":213,"minAge":214,"maxAge":215,"enrollmentInfo":216,"targetDuration":4,"studyType":22,"phases":218,"briefSummary":219,"conditions":220,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":232},"100561515","lifestyle-changes-in-pcos-with-osa-and-nafld-100561515","NCT06591169","Lifestyle Changes in PCOS with OSA and NAFLD","Polycystic Ovarian Syndrome Women with NAFLD and Obstructive Sleeping Apnea: Program of Lifestyle Changes","Inclusion Criteria:\n\n* forty women\n* women complaint PCOS\n* women complain obstructive sleep apnea\n* women are obese\n* women complain fatty liver\n\nExclusion Criteria:\n\n* cardiac insult\n* renal insult\n* malignacy\n* pregnancy","FEMALE","30 Years","40 Years",{"count":217,"type":21},40,[24],"Complain of obstructive sleeping apnea and fatty liver is common in PCOS women so lifestyle changes are recommended",[221,222,29],"PCOS","NAFLD","2024-09-09",{"date":225,"type":39},"2024-09-19",{"date":227,"type":39},"2024-07-05",{"date":229,"type":21},"2024-12-15",{"name":231,"class":103},"Cairo University",2,{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":17,"minAge":80,"maxAge":142,"enrollmentInfo":241,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":243,"conditions":244,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":254},"100472739","long-term-benefits-of-cpap-or-mad-treatment-on-the-sleep-of-osas-patients-100472739","NCT05435794","Long-term Benefits of CPAP or MAD Treatment on the Sleep of OSAS Patients","Long-term Benefits of Continuous Positive Pressure Therapy or Mandibular Advancement Devise on the Sleep of Patients With Obstructive Sleep Apnea","REMAP","Inclusion Criteria:\n\n* Patient already included in the SunSAS study (No. ID\u002FRCB: 2021-A01827-34) or Patient who has undergone polygraphy or polysomnography eligible for treatment with CPAP or MAD in the context of OSA.\n* Patient with a sleep test performed with the Sunrise device\n* Men or Women from 18 to 80 years old\n* Patient with OSAS eligible for CPAP or MAD therapy\n* Affiliated patient or beneficiary of a social security scheme\n* Signed informed consent\n\nExclusion Criteria:\n\n* Patient previously treated for OSAS by CPAP or MAD during the last five years\n* Patient with COPD or other respiratory diseases.\n* Patient with contraindications to PPC or MAD therapy\n* Patient with unstable heart disease or New York Heart Association class III or IV heart failure\n* Patient unable to complete the study",{"count":242,"type":21},400,"The REMAP study aims to follow a cohort of 400 patients in around ten sleep centers in France and to collect clinical routine data. The objectives of this study are to investigate the effects of one-year management of OSA by CPAP or MAD on sleep architecture defined by objective macro and micro sleep architecture parameters using a sleep test device. sleep connected at home, to assess the quality of sleep and the quality of life reported by patients. The study will also allow us to define predictive factors for improving sleep quality during OSA treatment.",[29],"2024-05-17",{"date":247,"type":39},"2024-05-21",{"date":249,"type":39},"2022-07-15",{"date":251,"type":21},"2026-10-15",{"name":253,"class":46},"ResMed",9,{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":17,"minAge":191,"maxAge":142,"enrollmentInfo":261,"targetDuration":4,"studyType":22,"phases":262,"briefSummary":265,"conditions":266,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":273,"locationsCount":72},"100523089","phase-1-acetazolamide-as-a-means-to-mitigate-falling-ventilatory-drive-and-drive-dependent-osa-100523089","NCT06091085","Acetazolamide as a Means to Mitigate Falling Ventilatory Drive and Drive-dependent OSA","Inclusion Criteria:\n\n* Ages 21-80 years\n* Suspected OSA (snoring, sleepiness, witnessed apneas, other clinical symptoms) or diagnosed OSA (severity not required)\n* Untreated; No use of OSA treatments within 2 weeks of the baseline study. No plans to start OSA treatments for the duration of the study protocol\n\nExclusion Criteria:\n\n* Any unstable medical condition\n* Current use of the study medication.\n* Use of ventilatory stimulant or depressant medications that may complicated interpretation of results (including opioids, barbiturates, doxapram, almitrine, theophylline, 4-hydroxybutanoic acid).\n* Contraindications for acetazolamide, including:\n* Allergies to sulfonamides - e.g. acetazolamide, hydrochlorothiazide, furosemide, sulfasalazine, celecoxib, sumatriptan, and zonisamide.\n* closed-angle glaucoma\n* adrenal insufficiency\n* known electrolyte or acid\u002Fbase imbalance (hyponatremia, hypokalemia, hyperchloremia, metabolic acidosis, acidemia)\n* clinically-significant kidney disorders (eGFR\\\u003C60 ml\u002Fmin\u002F1.73m2)\n* clinically-significant liver disorders\n* Use of more than 500 mg\u002Fday of Aspirin, due to the potential for an interaction of acetazolamide and very high doses of Aspirin (acetylsalicylic acid, a salicylate drug)\n* Adrenocortical insufficiency\n* Low sodium or potassium\n* hyperchloremic acidosis\n* Conditions likely to affect obstructive sleep apnea physiology: neuromuscular disease or other major neurological disorder, heart failure, or any other unstable major medical condition.\n* Respiratory disorders other than obstructive sleep apnea:\n* central sleep apnea (\\>75% of respiratory events scored as central)\n* chronic hypoventilation\u002Fhypoxemia (awake SaO2 \\\u003C 92% by oximetry) due to chronic obstructive pulmonary disease or other respiratory conditions\n* Conditions likely to increase arousability from sleep: insomnia\n* Other sleep disorders that may complicate establishment of sleep: periodic limb movements (periodic limb movement arousal index \\> 10\u002Fhr), narcolepsy, or parasomnias\n* For intramuscular electrodes and catheter: allergy to lidocaine\n* Highly-sensitive gag reflex. Patients with a self-reported 'highly-sensitive gag reflex', including an affirmative response to 'Do you sometimes gag when brushing your teeth?', will not take part in the physiology studies given the placement of an esophageal catheter\n* For intramuscular electrodes: use of aspirin or other oral anti-platelets \u002F anti-coagulants\n* For oronasal mask: severe claustrophobia\n* Pregnancy or nursing",{"count":193,"type":21},[263,264],"PHASE1","PHASE2","Obstructive sleep apnea (OSA) is a highly prevalent disorder that has major consequences for cardiovascular health, neurocognitive function, risk of traffic accidents, daytime sleepiness, and quality of life. For years, a \"classic\" model of OSA has been used to describe the disorder, which fails to capture it's complexity. Recently, a model for OSA called drive-dependent OSA was discovered be more prevalent in the OSA population. This drive-dependent OSA is due to ventilation instability that occurs during respiratory events however these individuals have spontaneous increases in drive during respiratory events that stabilize their airway (i.e., via improving upper airway muscle activity) and reduce the risk of respiratory events in people with OSA. Therefore, by stabilizing the ventilatory drive, OSA should be treatable. Acetazolamide is a pharmacological ventilatory stimulant and has been previously shown to reduce OSA severity. As such in this study, the goal is to demonstrate acetazolamide improves OSA severity in 'drive-dependent' OSA people by improving drive-related pharyngeal obstructions compared to the 'classic' OSA people.",[29],"2024-03-01",{"date":269,"type":39},"2024-03-04",{"date":271,"type":39},"2024-01-31",{"date":203,"type":21},{"name":205,"class":103}]